Bcl10 and methylation of fatty acids: a future therapeutic target for Type 2 diabetes?

References

• Jornayvaz FR, Shulman GI. Diacylglycerol activation of protein kinase Cepsilon and hepatic insulin resistance. Cell Metab. 15(5), 574–584 (2012).
   Google Scholar
• Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications.Hepatology 51(2), 679–689 (2010).
   Google Scholar
• Samuel VT, Liu ZX, Qu X et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 279(31), 32345–32353 (2004).
   Google Scholar
• Jornayvaz FR, Birkenfeld AL, Jurczak MJ et al. Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. Proc. Natl Acad. Sci. USA 108(14), 5748–5752 (2011).
   Google Scholar
• Jornayvaz FR, Jurczak MJ, Lee HY et al. A high-fat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gain. Am. J. Physiol. Endocrinol. Metab. 299(5), e808–e815 (2010).
   Google Scholar
• Jornayvaz FR, Lee HY, Jurczak MJ et al. Thyroid hormone receptor-alpha gene knockout mice are protected from diet-induced hepatic insulin resistance.Endocrinology 153(2), 583–591 (2012).
   Google Scholar
• Lee HY, Birkenfeld AL, Jornayvaz FR et al. Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology 54(5), 1650–1660 (2011).
   Google Scholar
• Kumashiro N, Erion DM, Zhang D et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc. Natl Acad. Sci. USA 108(39), 16381–16385 (2011).
   Google Scholar
• Schmid AI, Szendroedi J, Chmelik M, Krssak M, Moser E, Roden M. Liver ATP synthesis is lower and relates to insulin sensitivity in patients with Type 2 diabetes.Diabetes Care 34(2), 448–453 (2011).
   Google Scholar
• Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab. 14(6), 804–810 (2011).
   Google Scholar
• Petersen KF, Dufour S, Savage DB et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc. Natl Acad. Sci. USA 104(31), 12587–12594 (2007).
   Google Scholar
• Rabol R, Petersen KF, Dufour S, Flannery C, Shulman GI. Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo lipogenesis in insulin resistant individuals. Proc. Natl Acad. Sci. USA 108(33), 13705–13709 (2011).
   Google Scholar
• Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J. Clin. Invest. 116(7), 1793–1801 (2006).
   Google Scholar
• Baker RG, Hayden MS, Ghosh S. NF-kB, inflammation, and metabolic disease. Cell Metab. 13(1), 11–22 (2011).
   Google Scholar
• Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J. Biol. Chem. 276(20), 16683–16689 (2001).
   Google Scholar
• Ruland J, Duncan GS, Elia A et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. Cell 104(1), 33–42 (2001).
   Google Scholar
• Wegener E, Krappmann D. CARD-Bcl10-Malt1 signalosomes: missing link to NF-kappaB. Sci. STKE 384, pe21 (2007).
   Google Scholar
• van Beek M, Oravecz-Wilson KI, Delekta PC et al. Bcl10 links saturated fat overnutrition with hepatocellular NF-kappaB activation and insulin resistance. Cell Rep. 1(5), 444–452 (2012).
   Google Scholar
• Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with Type 2 diabetes. Diabetes 54(3), 603–608 (2005).
   Google Scholar
• Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45(7), 881–885 (1996).
   Google Scholar
• Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE. The effects of salsalate on glycemic control in patients with Type 2 diabetes: a randomized trial.Ann. Intern. Med. 152(6), 346–357 (2010).
   Google Scholar